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A major component of the cellular antiviral system is the latent protein kinase PKR, which is activated by binding to either double-stranded
RNA (dsRNA) or the cellular PACT protein. Activated PKR phosphorylates the translation initiation factor eIF2, thereby inhibiting viral and
cellular protein synthesis and virus replication. To evade the antiviral effects of PKR, many viruses, including influenza A virus, have evolved
multiple mechanisms. For influenza A virus, the non-structural (NS1A) protein plays a major role in blocking activation of PKR during virus
infection. The mechanism by which the NS1A protein inhibits PKR activation in infected cells has not been established. In the present study,
we first carried out a series of in vitro experiments to determine whether the NS1A protein could utilize a common mechanism to inhibit PKR
activation by both PACT and dsRNA, despite their different modes of activation. We demonstrated that the direct binding of the NS1A protein
to the N-terminal 230 amino acid region of PKR can serve as such a common mechanism and that this binding does not require the RNA-
binding activity of the NS1A protein. The lack of requirement for NS1A RNA-binding activity for the inhibition of PKR activation in vivo was
established by two approaches. First, we showed that an NS1A protein lacking RNA-binding activity, like the wild-type (wt) protein, blocked
PKR activation by PACT in vivo, as well as the downstream effects of PKR activation in cells, namely, eIF2 phosphorylation and apoptosis. In
addition, we demonstrated that PKR activation is inhibited in cells infected with a recombinant influenza A virus expressing NS1A mutant
protein that cannot bind RNA, as is the case in cells infected with wild-type influenza A virus.
© 2006 Elsevier Inc. All rights reserved.Keywords: PKR; Influenza virus; Double-stranded RNA; PACT; Viral evasion; Interferon actionIntroduction
The Ser/Thr protein kinase, PKR, is constitutively expressed
in mammalian cells and is further increased by interferon
treatment (Hovanessian, 1989; Meurs et al., 1990). PKR needs
to be activated via a conformational change that is brought
about by binding to either of its activators, double-stranded
RNA (dsRNA) or the PACT protein (Galabru and Hovanessian,
1987; Ito et al., 1999; Patel and Sen, 1998; Williams, 1999).
Activation results in PKR autophosphorylation, and the
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doi:10.1016/j.virol.2006.01.005(see below). Recent evidence indicates that the modes of
activation by dsRNA and PACT differ. The current model for
dsRNA activation is that an intramolecular interaction between
the N-terminal and C-terminal domains of PKR keeps the
protein in the inactive conformation and that the binding of
dsRNA to the two dsRNA-binding motifs (dsRBM1 and
dsRBM2) in the N-terminal domain of PKR releases the C-
terminal kinase domain, thus activating the enzyme (Nanduri et
al., 2000). In contrast, in PACT activation, one of its domains
(domain 3) binds to the C-terminal domain of PKR, releases it
from its interaction with the N-terminal domain and thereby
activates its kinase domain (S. Li, G. Peters, K. Ding, X. Zhang,
J. Qin and G. C. Sen, unpublished results). Although PACT is a
dsRNA-binding protein, its dsRNA-binding activity, which is
possessed by each of two domains (domains 1 and 2), is not
required for PKR activation. Rather, domain 3 of PACT, which
Fig. 1. NS1A blocks activation of PKR by PACT in vitro in a dose-dependent
manner. The effects of increasing concentrations of purified NS1A protein on
PRK activation by wt PACTwere tested. PKR activation assays were performed,
and PKR activation levels were quantified by PhosphorImager analysis and
presented in the bottom chart. PKR was incubated with purified PACT (15 nM)
as an activator in the absence of added protein (lane 2), in the presence of the
indicated concentrations of purified GST-NS1A protein (lanes 3 to 5) or in the
presence of the indicated concentrations of purified GST protein (lanes 6 to 8),
as described in Materials and methods. As a control, buffer was added to the
PKR activation reaction (lane 1). Arrow indicates 32P-labeled PKR.
14 S. Li et al. / Virology 349 (2006) 13–21does not bind dsRNA, is necessary and sufficient for activating
PKR (Peters et al., 2001).
Activated PKR blocks cellular and viral protein synthesis
by phosphorylating the α subunit of the eIF2 translation
initiation factor (eIF2α), thereby inhibiting viral replication in
infected cells (Gale and Katze, 1998; Samuel, 1993). Thus,
PKR plays a central role in host defense against viral infection.
To evade the antiviral effects of PKR, viruses have evolved
multiple strategies to block PKR activation or action (Gale and
Katze, 1998). It has been reported that influenza A virus uses
two such strategies: its non-structural (NS1A) protein blocks
PKR activation; and viral infection activates a cellular
inhibitor of PKR, p58IPK (Lu et al., 1995; Melville et al.,
1997; Tan et al., 1998). The mechanism by which the NS1A
protein inhibits PKR activation in infected cells has not been
established. The NS1A protein contains an RNA-binding
domain, which is comprised of its N-terminal 73 amino acids
and which binds dsRNA with low affinity (Chien et al., 1997,
2004; Hatada and Fukuda, 1992; Liu et al., 1997; Qian et al.,
1995). The NS1A protein via its RNA-binding domain can
block PKR activation by dsRNA in vitro (Hatada et al., 1999;
Lu et al., 1995). However, because the NS1A RNA-binding
domain has a much lower affinity for dsRNA than the dsRNA-
binding domains of PKR (Chien et al., 2004), it is not clear
that the NS1A protein can inhibit PKR activation by
effectively competing with PKR for dsRNA in vivo. Experi-
ments using mutant influenza A viruses have not established
that the RNA-binding domain of the NS1A protein is required
for the inhibition of PKR activation in infected cells (Donelan
et al., 2004; Hatada et al., 1999). Consistent with a different
mechanism, namely that direct interaction of the NS1A protein
with PKR blocks its activation, it has been reported that the
NS1A protein binds PKR in infected cells (Tan and Katze,
1998). However, such an NS1A–PKR interaction in infected
cells was not found by another group of investigators (Falcon
et al., 1999).
To gain insights into the mechanism of NS1A-mediated
inhibition of PKR activation, we first carried out a series of in
vitro experiments to determine whether the NS1A protein could
utilize a common mechanism to inhibit PKR activation by both
PACT and dsRNA, despite their different modes of activation.
We demonstrate that the direct binding of the NS1A protein to
PKR can serve as such a common mechanism. Thus, although
the NS1A protein can bind to PACT, we show that binding of
NS1A to PKR, but not to PACT, is responsible for blocking
PKR activation by PACT in vitro. Furthermore, we show that
PKR binding by the NS1A protein, as well as its mutant that is
defective in binding dsRNA, inhibits PKR activation by dsRNA
as well as by PACT. We then show that the NS1A protein and its
mutant defective in dsRNA-binding block PACT-mediated
PKR activation and the resultant eIF2α phosphorylation in
vivo. Finally, we demonstrate that PKR activation is inhibited in
cells infected with a recombinant influenza A virus expressing
NS1 mutant protein that cannot bind RNA, as is the case in cells
infected with wild-type virus. These results, which establish that
the RNA-binding domain of the NS1A protein is not required
for blocking PKR activation in vitro and in vivo, provide arationale for determining whether the direct interaction of the
NS1A protein with PKR plays an important role in the blocking
of PKR activation during influenza A virus infection.
Results
The NS1A protein inhibits PKR activation mediated by PACT
PKR can be activated by either dsRNA or the cellular PACT
protein (Clemens and Elia, 1997; Galabru and Hovanessian,
1987; Patel and Sen, 1998). To determine whether the influenza
virus NS1A protein inhibits PKR activation mediated by PACT,
increasing amounts of glutathionetransferase (GST)-NS1A
protein were added to PKR in the presence of PACT (Fig. 1).
In this in vitro assay, we used PKR that had been purified from
human cell extracts and an equal amount (15 nM) of purified
recombinant PACT. Activation of PKR was measured by its
autophosphorylation. Without added PACT, there was only a
low level of phosphorylation of PKR (lane 1, Fig. 1, top), which
was substantially increased upon addition of the PACT activator
to the reaction mixture (lane 2). These results demonstrated that
the PKR preparation was virtually free of any co-purified
activator, such as dsRNA, and that the PACT preparation was
highly active. When the GST-NS1A protein was added to the
reaction, we observed a dose-dependent inhibition of PKR
autophosphorylation (lanes 3–5). The same amounts of GST
protein had little effect (lanes 6–8), indicating that the observed
inhibition of PKR activation by GST-NS1A was due to the
NS1A part of the fusion protein. Quantitation of the intensities
Fig. 3. NS1A blocks PKR activation by binding to PKR, not PACT. (A) NS1A
blocks PKR activation by PACTΔ1. PKR activation assays in vitro were
performed to test the effects of increasing concentrations of NS1A protein on
PACTΔ1-mediated PKR activation. PACTΔ1 was used at 15 nM concentration.
Lane 1, buffer control; lane 2, PACTΔ1 alone; lanes 3 and 6, 27 nM GST
proteins; lanes 4 and 7, 81 nM GST proteins; lanes 5 and 8, 270 nM GST
15S. Li et al. / Virology 349 (2006) 13–21of the bands demonstrated that NS1A, at the highest dose,
almost completely blocked PKR activation by PACT (Fig. 1,
bottom).
The binding of the NS1A protein to PKR residues 1–230 is
responsible for the inhibition of PACT-mediated activation of
PKR
To identify the protein–protein interactions that are respon-
sible for the inhibition of PACT-mediated inhibition of PKR
activation, GST-NS1Awas used in a GST pulldown assay with
PKR (Fig. 2A) and PACT (Fig. 2B). The GST-NS1A protein,
but not GST, bound to PKR (Fig. 2A, lanes 1 and 5). To
determine the region of PKR to which the NS1A protein binds,
we tested a series of C-terminal deletion mutants of PKR for
binding to GST-NS1A. The GST-NS1A protein bound to PKR
(1–300) and full-length PKR strongly (lanes 1 and 2), and also
bound to PKR (1–230) (lane 3), but not to PKR (1–170) (lane
4). These results demonstrate that the NS1A protein requires
residues 1–230 of PKR for binding. In contrast, dsRNA
requires only residues 1–170 of PKR for binding (Feng et al.,
1992; Green and Mathews, 1992; Katze et al., 1991;
McCormack et al., 1992; Patel and Sen, 1992).Fig. 2. NS1A binds to both PKR and PACT. (A) NS1A binds to PKR residues 1
to 230. The binding of GST-NS1A to PKR and truncated PKR mutants was
tested in GST pulldown assays. 0.5 μg of purified GST or 1 μg of purified GST-
NS1A protein was incubated with cell extracts containing V5-tagged PKR
proteins in binding buffer containing glutathione–Sepharose 4B. After binding,
the PKR protein constructs interacting with GST-NS1A protein were analyzed
by Western blotting with V5 antibody. 1–551, PKR(1–551); 1–300, PKR(1–
300); 1–230, PKR(1–230); 1–170, PKR(1–170). (B) PACT binds to NS1A, and
its domain 1 is necessary for this binding. One microgram of bacterially purified
wt PACT, PACTΔ1 missing domain 1 and PACTΔ3 lacking domain 3 was
incubated with 1 μg of purified GST-NS1A or 0.5 μg of GST protein, and GST
pulldown assays were performed. Western blot analysis was performed to detect
PACT proteins interacting with NS1A using anti-PACT domain 2 antibody. WT,
wt PACT, the bottom band in the lane for wt PACT is degraded product; Δ1,
PACT mutant missing domain 1; Δ3, PACT mutant missing domain 3.
proteins; (B) NS1A blocks PKR activation by PACT domain 3. PKR kinase
assays were done as above, except that 10 nM of MBP-3 was used as an
activator. (C) NS1A does not disrupt binding of PACT domain 3 to PKR.
Binding of MBP-3 to purified FLAG-tagged PKR was tested in the presence of
0.1 μg (lane 3), 0.3 μg (lane 4), 1 μg (lane 5) or 2 μg (lane 6) of purified GST-
NS1A protein. As controls, PKR was incubated with either immobilized MBP
(lane 1) or MBP-3 (lane 2) in the absence of NS1A protein. The PKR protein
interacting with MBP-3 was Western blotted with FLAG antibody.Similar pulldown assays demonstrated that the NS1A protein
also binds to PACT (lane 1, Fig. 2B). PACT has three
identifiable domains, all of which bind to PKR, but only the
binding of domain 3 leads to activation of PKR. In contrast,
only domain 1 of PACT is required for binding to the NS1A
protein. Thus, GST-NS1A bound strongly to PACTΔ3, missing
domain 3 (lane 3), but did not bind to PACTΔ1, missing domain
1 (lane 2). The latter result showed that domains 2 and 3, both
present in PACTΔ1, were not sufficient for binding to GST-
NS1A.
To determine whether the interaction with PKR or the
interaction with PACT was required for the observed NS1A
protein-mediated inhibition of PKR activation, we took
advantage of the fact that the NS1A protein did not bind to
either PACTΔ1 or MBP-3 (a fusion protein of PACT domain 3
with the maltose binding protein), each of which can activate
PKR. If the NS1A protein inhibited PKR activation caused by
PACTΔ1 or MBP-3, then such inhibition could only result from
the binding of the NS1A protein to PKR. In fact, this was the
case: NS1A inhibited activation of PKR by PACTΔ1 (Fig. 3A)
and MBP-3 (Fig. 3B) in a dose-dependent fashion. We conclude
that the binding of the NS1A protein to residues 1–230 of PKR,
but not to PACT, is responsible for the inhibition of PACT-
mediated PKR activation.
One possible mechanism by which the NS1A protein might
inhibit PKR activation by PACT would be by blocking the
Fig. 5. NS1A blocks PACT-activated phosphorylation of PKR and eIF2α in
stressed cells. HT1080 cells were cotransfected with FLAG-tagged PACT and
NS1A constructs, NS1M and NS1M (R38A), at 1:1 ratio and treated with 50 ng/
ml of actinomycin D for 1 h. As controls, cells were transfected with empty
vector or FLAG-PACT vector alone and left treated or untreated. Cell extracts
were then prepared and analyzed by SDS-PAGE and Western blotting. The top
panel shows phosphorylation level and protein level of PKR detected by anti-
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demonstrate that this is not the case. Increasing amounts of the
GST-NS1A protein did not inhibit binding of MBP-3 to PKR
(lanes 3–6). These results indicate that the observed inhibitory
effect of the NS1A protein on PKR activation is not mediated by
impairing the interaction of PACT domain 3 with PKR.
The binding of the NS1A protein to PKR blocks its activation
by dsRNA as well as by PACT and does not require dsRNA
binding by the NS1A protein
The NS1A protein binds dsRNA, albeit with a low affinity.
Previous experiments have shown that the NS1A protein via its
RNA-binding domain can inhibit PKR activation in vitro by
binding dsRNA. To determine whether the NS1A protein can
inhibit PKR activation independently of its dsRNA-binding
activity, when activation is mediated by either PACTor dsRNA,
we used a mutant NS1A protein in which the arginine (R) at
position 38 has been replaced by alanine (A). This R38Amutant
NS1A protein has little or no dsRNA-binding activity (Wang et
al., 1999). Like the wild-type NS1A protein, the R38A mutant
protein binds PKR strongly (Fig. 4A). The R38A mutant NS1A
protein inhibits PKR activation in a dose-dependent manner,
whether PKR is activated by PACT or by dsRNA (Fig. 4B).
Consequently, although the modes of PKR activation by
dsRNA and PACT differ, the binding of the R38A NS1AFig. 4. RNA-binding property of NS1A is not required for inhibition of PKR
activation by PACT and dsRNA. (A) Like wt NS1A, an RNA-binding deficient
NS1A mutant, NS1A(R38A), binds to PKR. The binding of wt NS1A and
NS1A(R38A) to FLAG-tagged PKR expressed fromHT1080 cells was tested by
GST pulldown assays. 0.5 μg of purified GST (lane 1), 1 μg of purified wt
NS1A protein (lane 2) or 1 μg of purified NS1A (R38A) (lane 3) was incubated
with cell extracts containing FLAG-tagged PKR and then precipitated by using
glutathione–Sepharose 4B. The FLAG-tagged PKR interacting with NS1A
proteins was analyzed by Western blotting with FLAG antibody. WT, GST-wt
NS1A; R38A, GST-NS1A (R38A). (B) NS1A (R38A) inhibits PKR activation
by PACT and dsRNA. In vitro kinase activation assays were performed using
PACT (upper panel) or dsRNA (lower panel) as the activator, in the presence of
increasing concentrations of GST-tagged NS1A(R38A) protein. Lane 1, buffer
control; lanes 2 to 5, 15 nM PACT (upper panel) or 1 μg/ml dsRNA (lower
panel); lane 3, 27 nM NS1A(R38A) protein; lane 4, 81 nM NS1A(R38A)
protein; lane 5, 270 nM NS1A(R38A) protein.
phospho-PKR (P-PKR) and anti-PKR antibodies (PKR). The second panel
shows phosphorylation level and protein level of eIF2α detected by antibodies
against phospho-eIF2α (P-eIF2α) and eIF2α. The third and the bottom panels
show expression of PACT and NS1A proteins detected by Western blot analysis
with anti-FLAG antibody and anti-NS1A antibody, respectively. NS1M, NS1A
missing residues 184–188 required for CPSF binding and inhibition of cellular
gene expression; NS1M (R38A), NS1Awith R38A mutation and with deletion
of residues 184–188.mutant protein to PKR in vitro inhibits PKR activation mediated
by both these activators.
The NS1A protein inhibits PKR activation by PACT in vivo
When cells expressing PACT are subjected to extracellular
stress, by treatment with a very low dose of actinomycin D,
PKR is phosphorylated (activated), and, as a consequence,
eIF2α is phosphorylated (Patel et al., 2000; Peters et al., 2001).
We determined whether the NS1A protein inhibits both PACT-
mediated PKR activation and the resulting eIF2α phosphor-
ylation. HT1080 cells, which express very little PACT (Patel
and Sen, 1998; Peters et al., 2001), were transfected with a
vector expressing PACT. Treatment of these cells with
actinomycin D activated PKR, as measured by its phosphor-
ylation (Fig. 5, top panel, lane 3) and the consequent
phosphorylation of eIF2α, a major target of PKR (Fig. 5,
second panel, lane 3). These phosphorylations were dependent
on PACT expression because they did not take place after
actinomycin D treatment of cells transfected with an empty
vector (Fig. 5, lane 1). To determine whether the NS1A protein
inhibited these two phosphorylations, a plasmid expressing the
NS1A protein was cotransfected with the PACT expression
Fig. 7. Both wt and R38A mutant influenza A viruses inhibit PKR activation in
infected cells. Recombinant influenza A viruses encoding wt NS1 and dsRNA-
binding deficient NS1 mutant NS1(R38A) were generated using the 12-plasmid
transfection system (Takeda et al., 2002). A549 cells were mock-infected or
infected with the recombinant viruses for 7 h. VSV infection of A549 cells can
activate PKR and thus was used as a PKR activation control. Cell extracts were
prepared and subjected to SDS-PAGE and Western blotting analysis. The top
panel shows phosphorylation level of PKR detected by anti-phospho-PKR
antibody. The middle panel shows phosphorylation level of eIF2α detected by
anti-phospho-eIF2α. The bottom panel shows total PKR protein detected by
anti-PKR antibody.
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processing of cellular pre-mRNAs, including pre-mRNAs
expressed from plasmids under the control of polymerase II
promoters, we expressed a mutant form of the NS1A protein
(NS1M) that lacks this function (Noah et al., 2003). Both the
NS1M protein and its R38A mutant (NS1M(R38A)) blocked
the phosphorylation of both PKR and eIF2α in vivo (Fig. 5,
lanes 4 and 5). PACT was expressed at similar levels in all
transfected cells (Fig. 5, third panel), and the NS1M and
NS1M(R38A) proteins were expressed equally well (Fig. 5,
bottom panel), thus validating these results.
We have developed a quantitative cell survival assay to
measure apoptosis resulting from PACT-mediated activation of
PKR. In this assay, an expression vector of PACT is
cotransfected with a GFP expression vector. After treatment
with a low level of actinomycin D, live transfected cells are
identified by their GFP expression and counted by FACS.
Almost all (approximately 90%) of the PACT-expressing cells
are killed upon actinomycin D treatment (Fig. 6, lane 2). When
cells are transfected with a vector for expressing only GFP, but
not PACT, they are not killed by the actinomycin D treatment
(data not shown). Co-expression of the NS1M or the NS1M
(R38A) protein efficiently protected the cells from PACT-
mediated apoptosis (Fig. 6, lanes 3 and 4). The results presented
in Figs. 5 and 6 demonstrate that, in vivo, the NS1A protein
blocks PACT-mediated PKR activation and the consequent
phosphorylation of eIF2α and cellular apoptosis. Moreover, the
RNA-binding activity of the NS1A protein is not required for
this protective effect.
The RNA-binding activity of the NS1 protein is not required for
inhibiting PKR activation in virus-infected cells
Finally, we confirmed that the above conclusions were true
for influenza-A-virus-infected cells as well. For this purpose, a
mutant influenza A virus that encodes the R38A mutant of the
NS1A protein was generated. Cells were infected with the wt or
the mutant virus, and PKR activation was monitored by
measuring the levels of PKR and eIF2α phosphorylationsFig. 6. NS1A blocks stress-induced PACT-mediated cell-killing. Cell survival
assays were performed to test the effects of NS1A proteins on PACT-mediated
cell-killing by monitoring the loss of EGFP-expressing cells after cotransfection
of indicated expression constructs with an EGFP expression vector. The error
bars represent the standard error calculated from three independent experiments.(Fig. 7). As controls of this experiment, we verified that both
proteins were highly phosphorylated in cells infected with VSV
(Fig. 7, lane 1), but not in mock-infected cells (Fig. 7, lane 2).
There was little PKR activation in cells infected with the wt
influenza A virus (Fig. 7, lane 3). The same was true for the
mutant virus expressing the R38A mutant of the NS1A protein
(Fig. 7, lane 4). These results conclusively demonstrate that the
RNA-binding property of the NS1 protein is not required for its
ability to block PKR activation in influenza-A-virus-infected
cells.
Discussion
Both dsRNA and PACT activate PKR, but via different
mechanisms. Although traditionally it has been thought that
viral dsRNA is the activator of PKR in virus-infected cells, there
is no compelling evidence in the literature to support this notion.
It is possible that viruses activate PACT, which in turn activates
PKR. Based on the concept that viruses would need to block
PKR activation by both dsRNA and PACT, we carried out in
vitro experiments to determine whether the NS1A protein of
influenza A virus, the viral protein that has been implicated in
the inhibition of PKR activation during virus infection
(Bergmann et al., 2000), can block PKR activation by both
activators. We established that this was indeed the case by
demonstrating that the binding of the NS1A protein to the N-
terminal 230 amino acid region of PKR is necessary and
sufficient to block PKR activation by both PACT and dsRNA in
vitro. The ability of the NS1A protein to bind to PKR and block
its activation by both activators does not require the RNA-
binding activity of the NS1A protein. Thus, the R38A mutant
NS1A protein, which lacks RNA-binding activity, effectively
binds to PKR and blocks its activation by both dsRNA and
PACT. Furthermore, we demonstrated that the RNA-binding
activity of the NS1A protein is not required for its ability to
inhibit PKR activation in vivo. Thus, we showed that the R38A
mutant NS1A protein, like the wild-type (wt) protein, blocks
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effects of PKR activation in cells, namely, eIF2α phosphoryla-
tion and apoptosis. In addition, the activation of PKR was
inhibited in cells infected by a recombinant influenza A virus
expressing an NS1A protein lacking RNA-binding activity.
These results raise two important issues. First, how does the
binding of the NS1A protein to PKR block the activation of
PKR by two activators (dsRNA and PACT) whose modes of
activation are quite distinct? This issue is also relevant for the
HSV-1 protein US11, which has little sequence homology with
NS1A, but can similarly block PKR activation by either dsRNA
or PACT (Peters et al., 2002). It is curious to note that both
NS1A and US11 proteins are RNA-binding proteins, but this
property of neither protein is required for inhibiting PKR
activation. Instead, what is required is the ability to bind PKR
directly. Although both proteins bind to the N-terminal region of
PKR, the exact binding sites are different. Residues 1–170 of
PKR are sufficient to bind US11, but not NS1A, which requires
residues 170–230 as well. Current information (S. Li et al.,
unpublished results) suggests that an intramolecular interaction
between the N-terminal region and the kinase domain of PKR is
responsible for keeping the protein in an inactive conformation
and the binding of dsRNA to the N-terminal region or the
binding of PACT domain 3 (PACTd3) to the kinase domain
causes the conformational change that activates PKR (Fig. 8A).
Results presented here indicate that the binding of NS1A to the
linker region of PKR, between the dsRNA-binding domain and
the kinase domain, blocks this conformational change (Fig. 8B).Fig. 8. Model for NS1A-mediated inhibition of PKR activation. (A) Binding of dsRN
domain disrupts the intramolecular interaction between dsRBM2 and the kinase dom
activation. (B) Binding of NS1A protein to residues to the linker region of PKR prev
bind to the kinase domain of PKR. Such a binding also blocks dsRNA-mediated PKThe block is not mediated by interfering with the PACTd3/PKR
interaction (Fig. 3C) but by strengthening the intramolecular
interaction between the two domains of PKR and freezing it in
an inactive state. This model is valid for the inhibitory action of
US11 as well (Peters et al., 2002). We believe that this
mechanism also holds true for PKR activation by dsRNA (Fig.
8B), in which case the PKR/dsRNA/NS1A complex remains
frozen in the inactive conformation, a postulate that can be
experimentally tested in the future. Note that the model does not
require an interaction between NS1A and dsRNA, which is
supported by our experimental results.
The second issue is: does the NS1A protein in influenza-A-
virus-infected cells utilize the mechanism described here,
namely, binding to the N-terminal region of PKR, to block
PKR activation? This mechanism would enable influenza A
virus to block activation by both dsRNA and PACT. However,
previous studies have provided conflicting results concerning
whether the NS1A protein interacts directly with PKR in
infected cells. An alternative mechanism for blocking PKR
activation is that the NS1A protein via its RNA-binding domain
sequesters dsRNA, rendering it unavailable for PKR activation.
This mechanism would inhibit only dsRNA activation, but not
PACT activation, of PKR. In addition, it is not clear whether the
NS1A RNA-binding domain is capable of sequestering dsRNA
away from PKR because the NS1A RNA-binding domain has a
much lower affinity for dsRNA than the two dsRNA-binding
domains in PKR (Chien et al., 2004; Green and Mathews,
1992). The results presented in Fig. 7 clearly show that thisA to PKR dsRBM1 and dsRBM2 or binding of PACT domain 3 to PKR kinase
ain of inactive PKR and induces similar conformational changes leading to its
ents PKR activation by PACT domain 3, even though PACT domain 3 can still
R activation.
19S. Li et al. / Virology 349 (2006) 13–21alternative mechanism does not operate in influenza-A-virus-
infected cells: PKR activation is blocked equally well by the wt
NS1 protein and the mutant NS1 protein that cannot bind RNA.
Hence, the results presented here provide a rationale for
determining whether the interaction of the NS1A protein with
PKR plays an important role in the blocking of PKR activation
during influenza A virus infection. These experiments have the
potential of determining the contribution of an additional
mechanism for the inhibition of PKR activation in influenza-A-
virus-infected cells by the cellular p58IPK protein.
Materials and methods
Cell lines
HEK293T, human embryonic kidney cells, HT1080 cells,
human fibrosarcoma cells and A549, human lung carcinoma
epithelial cells, were cultured in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
and antibiotics at 37 °C under a 5% CO2 atmosphere.
Antibodies and other reagents
Actinomycin D, FLAG peptide, anti-FLAG monoclonal M2
antibody and M2-agarose were obtained from Sigma-Aldrich
Corporation. Lipofectamine 2000 and anti-V5 monoclonal
antibody were purchased from Invitrogen Corporation. Anti-
PKR antibody was from Santa Cruz. Phospho-specific anti-
eIF2α, phospho-specific anti-PKR (against phosphorylated
threonine 445) and anti-eIF2α antibodies were purchased
from Cell Signaling Technology. PACT anti-domain 2 and
anti-domain 3 peptide antibodies (Peters et al., 2001, 2002)
were custom-produced by Bio-Synthesis, Inc. FuGENE 6
transfection reagent was from Roche. CaPO4 transfection
reagents were prepared according to Current Protocols in
Molecular Biology.
Expression vectors
The generation of FLAG-tagged and V5-tagged PKR
constructs, pcDNA3-PKR(K296R)-FLAG and pV5-PKR, and
FLAG-tagged PACT construct pcDNA3-FLAG-PACT as well
have been described previously (Goh et al., 2000; Peters et al.,
2001, 2002). pEGFP-C1 containing the cDNA coding for
enhanced green fluorescent protein was from Promega. To
generate V5-tagged PKR deletion mutants, DNA fragments
corresponding to residues 1–170, 1–230 and 1–300 of PKR
were amplified by PCR with primers containing restriction
sites BamHI and XbaI. The PCR products were ligated in-
frame into a V5-tagged vector, Vet (Goh KC, EMBO 2000). To
generate bacterial expression vectors containing GST-tagged
wt NS1A, the A/Udorn/72 NS1 full-length open reading frame
was PCR-amplified and cloned into the unique BamHI and
EcoRI sites of the pGEX-3X plasmid to allow expression as
GST fusion proteins. GST-tagged NS1A mutants with an
alanine substitution at arginine 38 (R38A) were generated by
using two rounds of PCR and specific oligonucleotide primers.The resultant DNA was cloned into BamHI/EcoRI-digested
pGEX-3X. To generate NS1A mammalian expression vector
containing a mutated binding site for the 30 kDa subunit of the
cleavage and polyadenylation-specific factor (CPSF), amino
acids 184 to 188 of the influenza A/Udorn/72 NS1A protein
were changed from GLEWN to RFLRY (NS1M) as described
previously (Noah et al., 2003), and the resulting DNA was
cloned into pcDNA3 vector. Its derived mutant containing
R38A mutation, NS1M(R38A), in pcDNA3 was also made as
described above. All the resulting DNA clones with internal
mutations were sequenced to verify the introduction of desired
mutations.
Purification of NS1A, PACT and their derivatives
GST-NS1A fusion proteins were purified as previously
described (Qiu and Krug, 1994). The purity of GST-fusion
protein was established by SDS-PAGE followed by coomassie
blue staining and Western blotting with anti-GST antibody
(Amersham). Bacterial expression and purification of wt PACT,
PACTΔ1, PACTΔ3, and the fusion protein of maltose binding
protein (MBP) and PACT domain 3, MBP-3, were described
previously (Peters et al., 2001, 2002).
PKR kinase assay in vitro
PKR activation assays were performed using ectopically
expressed V5-tagged PKR (Yin et al., 2003). V5-PKR was
expressed in HEK293T cells by CaPO4 transfection and
immunoprecipitated with anti-V5 monoclonal antibody. Kinase
assay was done in activity buffer containing: immobilized PKR,
an activator (dsRNA, purified wt PACT, PACTΔ1 or MBP-3)
and 1 μCi of [γ-32P]ATP at 30 °C for 30 min. To test the effects
of purified GST-wt NS1A or GST-NS1A(R38A) mutant on
PKR activation, PKR immunoprecipitate was incubated with
purified GST-NS1A proteins or GST protein control at 4 °C for
5 min followed by addition of a purified PKR activator and [γ-
32P]ATP. As a control, neither PKR activator nor GST proteins
was added to the PKR activation reaction. Autophosphorylated
PKR was analyzed by SDS-PAGE and visualized by auto-
radiography. PKR activation levels were quantified by Phos-
phorImager analysis and presented as a chart. The amount of
radioactivity in PKR in the absence of any added purified
protein was regarded as background and subtracted from all
other values. The amount of radioactivity in PKR activated by
an activator alone was considered 100%, and the values for GST
proteins are presented as percentages of that value.
Assay for binding of PACT domain 3 to PKR
Purification of PKR(K296R)-FLAG protein and in vitro
PACT domain 3-PKR binding assay were described previously
(Peters et al., 2002). To test the effect of NS1A protein on
binding of MBP-3 to PKR, increasing amounts of GST-NS1A
protein were pre-incubated with 0.5 μg resin-bound MBP or
MBP-3 in binding buffer (20 mM Tris–HCl, 10 mM β-
mercaptoethanol, 1 mM EDTA and 10% glycerol, pH 7.5) at 4
20 S. Li et al. / Virology 349 (2006) 13–21°C for 5 min, and then 1 μg purified PKR(K296R)-FLAG
protein was added to the mixture and incubated at 4 °C for 1 h.
Proteins bound to the beads were analyzed by SDS-PAGE
followed by Western blot analysis with anti-FLAG antibody for
detecting PKR(K296R)-FLAG and anti-PACT domain 3 anti-
body for detecting MBP-3.
GST pulldown assay
To analyze protein interactions between NS1A proteins and
PKR or PACT proteins, GST or GST-NS1A proteins were
mixed with cell extracts containing V5-tagged or FLAG-tagged
PKR proteins in binding buffer A (20 mM Tris–HCl, 50 mM
NaCl, 0.4% Triton X-100, 20% glycerol, 100 units/ml aprotinin,
0.2 mM PMSF, pH 8.0) or with bacterially purified PACT
proteins in binding buffer B (20 mM Tris–HCl, 200 mM NaCl,
1% Triton X-100, 20% glycerol, 100 units/ml aprotinin, 0.2 mM
PMSF, pH 8.0). After 1 h at 4 °C on a rotating wheel, 30 μl of
glutathione–Sepharose 4B (Amersham Pharmacia) (50% solu-
tion in binding buffer) was added, and the mixtures were spun
for 2 h. The beads were precipitated and washed three times
with 500 μl of binding buffer. The proteins binding to NS1A
proteins were analyzed by SDS-PAGE followed by Western
blot analysis with anti-FLAG antibody, anti-V5 antibody or
anti-PACT domain 2 antibody. GST proteins were detected with
anti-GST antibody.
Generation of recombinant influenza A/Udorn/72 virus from
cloned DNA
pHH21 plasmids containing the full-length cDNAs for each
of the eight influenza A/Udorn/72 genomic RNA segments and
four pcDNA plasmids encoding PB1, PB2, PA and NP of
influenza A/Udorn/72 were provided by Makoto Takeda
(Takeda et al., 2002). Alteration of Udorn NS1A residue 38
from R to A (R38A mutant) was performed by using two rounds
of PCR. The resulting DNA was sequenced and cloned into
pHH21. Viruses encoding the wild-type and R38A mutant
NS1A proteins were generated by cotransfecting 293T cells
with eight plasmids encoding the vRNA segments and four
plasmids expressing the PB1, PB2, PA and NP proteins (Takeda
et al., 2002). At various times posttransfection, culture super-
natants were collected. Viruses were titered by plaque assay on
MDCK cells, and individual plaques were amplified in 10-day-
old embryonic chicken eggs at 34 °C. Amplified virus was
titered by plaque assay on MDCK cells, and all the genomic
RNA segments were sequenced.
Analysis of the phosphorylations of PKR and eIF2α in vivo
To measure the phosphorylation levels of PKR and eIF2α
in transfected cells, HT1080 cells were transfected with
pcDNA3, or pcDNA3-FLAG-PACT alone, or pcDNA3-
FLAG-PACT together with NS1A constructs using Lipofecta-
mine 2000 reagent. Wt NS1A binds to the 30 kDa subunit of
CPSF, thereby inhibiting 3′-end processing of pre-mRNA of
cellular or transfected genes. To co-express PACT and NS1Ain cells, NS1A mutants [NS1M and NS1M(R38A)] deficient
in CPSF binding were used (Noah et al., 2003). After 47 h,
cells were treated with 50 ng/ml of actinomycin D for 1 h,
harvested and lysed in lysis buffer (20 mM Tris, 100 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.1 M phenylmethyl-
sulfonyl fluoride, 200 units/ml aprotinin, 100 μM vanadate, 1
mM NaF, 2 nM okadaic acid, 25 mM β-glycerophosphate, pH
8.0). Protein concentrations of cell lysates were measured by
the Bradford method (BioRad, CA). Cell extracts containing
50 μg of protein were resolved on SDS polyacrylamide gels.
FLAG-PACT and NS1A proteins were detected using anti-
FLAG antibody and NS1A antibody, independently. Phospho-
specific anti-eIF2α and phospho-specific anti-PKR antibodies
were used to detect phosphorylated proteins, and anti-eIF2α
and anti-PKR antibodies were used to detect PKR and eIF2α
protein levels.
To measure the phosphorylation levels of PKR and eIF2α in
virus-infected cells, confluent A549 cells in 35 mm dishes were
infected with recombinant wild-type influenza A virus or R38A
mutant virus at an moi of 5 pfu/cell. As a positive control, A549
cells were infected with Vesicular Stomatitis Virus (VSV). At 7
h post-infection, cells were treated with 25 μM protein
phosphatase inhibitor, Calyculin A, for 30 min. Cells were
then washed with cold PBS, and RIPA buffer (50 mM Tris–Cl
pH 7.5, 1% NP-40, 0.5% sodium deoxycolate, 0.05% SDS, 1
mM EDTA, 150 mM NaCl) containing protease inhibitor was
added to lyse the cell. Total cell lysates were analyzed for PKR
phosphorylation and eIF2α phosphorylation as described
above.
Cell survival assay
HT1080 cells were cotransfected with pcDNA3, or
pcDNA3-FLAG-PACT, or pcDNA3-FLAG-PACT with
NS1M or NS1M(R38A) construct, as well as pEGFP-C1
using Lipofectamine 2000 transfection reagent. The total
amount of DNA used was 8.5 μg, and the ratio of FLAG-
PACT:NS1A consruct:pEGFP-C1 was 3.75:3.75:1. At 6 h
after transfection, cells were treated with 50 ng/ml of
actinomycin D for inducing PACT-mediated apoptosis (Peters
et al., 2001). At 48 h after transfection, the media containing
dead cells was removed and cells remaining on the plates
were washed with PBS three times and collected. By using
flow cytometry, effects of NS1A proteins on cell-killing by
PACT were analyzed by comparing the percentages of EGFP-
expressing cells for transfection with vector control, transfec-
tion with PACT alone and transfections with PACT and NS1A
constructs. The cell survival value for vector transfection is
considered 100%, and the values for other transfections are
presented as percentage of that value.
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